|
|
| Maladies Cardiovasculaires > Etude de marché sectorielle |
| The Cardiovascular Outlook 2000 |
|
|
|
|
€ 955,00 |
Editeur
: |
Business Insight |
Langue
: |
Anglais |
Date de publication : |
Septembre 2000 |
Taille du document : |
161 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
Documents Publics |
1,200,000
documents |
Téléchargement illimités |
|
|
|
Etudes Privées |
50,000 rapports et études |
Paiement à la piéce |
|
|
|
|
| |
|
1.Télécharger nos rapports publics
Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...
|
| Nos documents publics sur le même théme (2) |
|
|
|
| 56 pages | Février 2007 | Anglais
|
|
|
| Main
focus: |
pharmaceutical,pharmaceutical industry,...,...
|
| Research
focus: |
pricing policy,market definition, |
| Geographic
focus: |
australia,france,usa,spain,ireland,italy,... |
| |
|
|
|
|
| 158 pages | Juin 2005 | Anglais
|
|
|
| Main
focus: |
pharmaceutical,pharmaceutical industry,...,...
|
| Research
focus: |
industry structure,distribution channels, |
| Geographic
focus: |
usa,france,china,italy,japan,united kingdom,... |
| |
|
|
|
|
| Autres recherches sur le même thème |
|
|
|
| |
| |
|
| |
|
2.
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Strategies in Nutraceuticals: Functional Food and Drinks
163 pages | Janvier 1999 |
The nutraceuticals market has been an important area of development for food, drinks, ingredients and pharmaceutical companies since the beginning of the 1990s.
Products such as Red Bull, Nut |
795,00 €
|
| |
| |
PharmaVitae 2005: Novo Nordisk Global and US Analysis
148 pages | Octobre 2005 |
IntroductionThis analysis examines the current position and future outlook for Novo Nordisk in the ethical pharmaceutical sector.
The profile encompasses global company strategy, portfolio and pipe |
4 845,00 €
|
| |
| |
Pipeline Insight: Antithrombotics - Anticoagulants and Antiplatelets Have Blockbuster Potential
383 pages | Octobre 2005 |
IntroductionDatamonitor estimates the total revenue generated from new antithrombotics in the seven major markets will reach approximately $10bn by 2015, with novel oral anticoagulants contributing ov |
9 690,00 €
|
| |
| |
Commercial Insight: Cancer Market Top 20 Drugs - Supportive Care Grows the Cancer Market
92 pages | Janvier 2005 |
IntroductionThe global cancer market is predicted to grow at a CAGR exceeding 10%.
However, a number of global and country-specific factors will support or threaten this trend including epidemiolog |
12 160,00 €
|
| |
| |
The Cardiovascular Outlook 2000
161 pages | Septembre 2000 |
In 1999, cardiovascular drugs represented the largest single segment of the global pharmaceutical industry by value.
Estimated sales of $69.6bn represented growth of 8.2% over 1998 levels.
|
955,00 €
|
| |
| |
Cardiac Pacemakers
237 pages | Octobre 2005 |
This report analyzes the worldwide markets for Cardiac Pacemakers in Millions of US$.
The major product segments analyzed are Implantable Pacemakers, and External Pacemakers.
The sub product seg |
3 091,00 €
|
| |
| |
PROactive Results - The Diabetes Trial That Could Have Been
40 pages | Novembre 2005 |
IntroductionThe socio-economic consequences of diabetes and its complications make it a major public health issue.
Patients with diabetes have a 25% reduction in life expectancy compared with the g |
3 230,00 €
|
| |
| |
The Cardiovascular Outlook 1998-2010
186 pages | Août 1999 |
In 1998, the global cardiovascular market expanded by 7.2%, growing in value from $60bn in 1997 to almost $65bn in 1998.
Market expansion is being driven by expanding prevalent populations in t |
795,00 €
|
| |
| |
Hemoglobin A1c Monitoring
245 pages | Octobre 2005 |
This report analyzes the worldwide markets for Hemoglobin A1c Monitoring in Millions of US$.
The specific product segments analyzed are HbA1c Laboratory Testing, and HbA1c Point of Care Testing & S |
3 091,00 €
|
| |
| |
Low and Light Outlook to 2006 Growth opportunities in diet and health food and drinks
150 pages | Février 2002 |
Taste continues to be seen as the number one driving force behind any product purchase, whilst fat content and calorie concerns are losing out to specific health benefits.
Low and Light Outlook |
953,48 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| The Cardiovascular Outlook 2000 |
|
|
In 1999, cardiovascular drugs represented the largest single segment of the
global pharmaceutical industry by value.
Estimated sales of $69.6bn represented growth of 8.2% over 1998 levels.
Although anti-hypertensives generate significantly higher revenues than other
sectors of the cardiovascular market, this class of drugs is dominated by older
products, is highly genericized and is noted for its slow rate of growth.
However, expansion in the lipid lowering class, driven chiefly by the statins,
is increasingly compensating for this.
The Cardiovascular Outlook 2000 is based upon an extensive primary research
program encompassing companies active at all levels of the cardiovascular arena,
ranging from small biotechs to big pharma.
Building upon this research, key market data is allied to competitive analysis
to provide historical and forecast future product sales, along with strategic
insight into how companies are positioning themselves to exploit opportunities
in this prominent market.
We have the answers for you:
• Within the cardiovascular market, which products have recorded significant
revenues in recent years?
• How are competing companies positioning themselves within this high-value
market?
• In which areas are companies currently focusing their R&D resources?
• Which innovative therapies will reach the market within the next five years
and what will be their impact?
• What are the optimum components of a successful cardiovascular franchise?
• To what extent will generic competition erode market share of branded products?
• What are the major unmet needs in the treatment of cardiovascular disease
and how can they be targeted?
|
|
Chapter 1: Cardiovascular disease overview
Chapter 2: Patient potential
Chapter 3: 1999 cardiovascular market review
Chapter 4: Company analysis
Chapter 5: The commercial implications of changing cardiovascular guidelines
Chapter 6: Cardiovascular market SWOT analysis
Chapter 7: Appendix
|
|
|
PPLSEN
|
|
|
|
|
